Antiplatelet and anticoagulation therapy for acute coronary syndromes

Deepak L Bhatt; Jean-Sébastien Hulot; David J Moliterno; Robert A Harrington

doi:10.1161/CIRCRESAHA.114.302737

Antiplatelet and anticoagulation therapy for acute coronary syndromes

Circ Res. 2014 Jun 6;114(12):1929-43. doi: 10.1161/CIRCRESAHA.114.302737.

Authors

Deepak L Bhatt¹, Jean-Sébastien Hulot², David J Moliterno², Robert A Harrington²

Affiliations

¹ From the Brigham and Women's Hospital and Harvard Medical School, Boston, MA (D.L.B.); Icahn School of Medicine at Mount Sinai, Cardiovascular Research Institute, New York, NY (J.-S.H.); Department of Medicine and Gill Heart Institute, University of Kentucky, Lexington (D.J.M.); and Stanford University, CA (R.A.H.). [email protected].
² From the Brigham and Women's Hospital and Harvard Medical School, Boston, MA (D.L.B.); Icahn School of Medicine at Mount Sinai, Cardiovascular Research Institute, New York, NY (J.-S.H.); Department of Medicine and Gill Heart Institute, University of Kentucky, Lexington (D.J.M.); and Stanford University, CA (R.A.H.).

PMID: 24902976
DOI: 10.1161/CIRCRESAHA.114.302737

Abstract

The past 2 decades have witnessed the introduction and demise of several different antithrombotic medications for acute coronary syndromes. Part of the assessment of these compounds has been their effect on thrombotic events relative to the degree of increase in bleeding events. This review will outline the data supporting various antiplatelet and anticoagulant therapies and their combinations in patients with acute coronary syndromes and related disorders in both the acute and chronic phases of therapy.

Keywords: acute coronary syndrome; hemorrhage; myocardial infarction.

Publication types

Review

MeSH terms

Acute Coronary Syndrome / drug therapy*
Anticoagulants / therapeutic use*
Humans
Myocardial Infarction / drug therapy*
Platelet Aggregation Inhibitors / therapeutic use*
Practice Guidelines as Topic

Substances

Anticoagulants
Platelet Aggregation Inhibitors